Kornimate/medical-research-clean huggingface dataset:
intranasal nafarelin for triggering oocyte maturation

Conditions: Fertility Disorders

Summary: this is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in oocyte donors undergoing ovarian stimulation.

oocyte donors meeting the inclusion criteria will be randomised to receive triggering for final oocyte maturation with 200 micrograms of subcutaneous triptorelin (control group) or 800 micrograms of intranasal nafarelin (experimental group). the primary outcome is the number of mature (metaphase 2 (mii)) oocytes collected. the study has been designed with a non-inferiority limit of a difference of 2 mature oocytes, with 80% power and one-sided alpha of 0.05.

Eligibility criteria:
inclusion criteria: * oocyte donor * undergoing a progesterone-primed ovarian stimulation cycle (ppos) with any commercially available gonadotropin preparation(s) * bmi 18 - 30 kg/m2 * ≥10 follicles of ≥14mm average diameter on the last ultrasound prior to trigger administration * able and willing to provide written informed consent exclusion criteria: * allergy or hypersensitivity to either of the study drugs * hypopituitarism * known pituitary tumour * contraindication to intranasal medication administration * previous poor response to agonist trigger

Keywords: ivf infertility oocyte donor gnrh agonist
increased tea consumption is associated with a decreased risk of renal stone disease in a taiwanese population

Conditions: Renal Stone

Summary: the objective of the this study was to examine the amount and duration of tea consumption in relation to the risk of renal stone disease.

previous studies have investigated the association between tea consumption and renal stone disease, but the results are still unclear. besides, the impact of the duration of tea consumption has not yet been investigated in the aforementioned studies. the present study was conducted as a retrospective research to investigate the relationship between both tea consumption amount and time and renal stone disease. information on tea consumption was obtained by four closed-ended questions in questionnaires, and the diagnosis of renal stones was established on the results of abdominal sonography.

Eligibility criteria:
inclusion criteria: * ≥ 18 years old exclusion criteria: * individuals with a history of hyperuricemia or gout at baseline, findings of abdominal ultrasound showing transplant kidney, only one kidney, or gouty nephropathy, or missing data

Keywords: tea, cup-year, renal stone disease
a single center randomized controlled trial assessing pain and quality of life following surgery

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to help us to better understand the effects of two different types of surgical techniques on pain and quality of life in patients with precancerous lesions or early stage mouth cancers.


Eligibility criteria:
inclusion criteria: * biopsy proven diagnosis or clinical diagnosis of any benign oral cavity lesion. pre-surgical biopsy will not be required if lesion is suspected to be benign. * biopsy proven diagnosis or clinical diagnosis of premalignant oral cavity lesions (leukoplakia, erythroplakia, lichen planus, dysplasia)pre-surgical biopsy will not be required if lesion is suspected to be benign. * biopsy proven diagnosis of small superficial oral cavity scc (stage t1n0) requiring resection without the need for neck dissection. * all pathology will be reviewed at msk to confirm diagnosis. * the lesion plus the resection margin should not exceed 4.0 cm circumferentially. * planned to undergo surgical treatment by resection without flap reconstruction and without neck dissection. * all patients age 18 years of age and older. * karnofsky performance score over 60. patients on blood thinners (aspirin or coumadin) will be asked to stop medications 7 days prior to surgery. in the case of coumadin, patients are switched to lovenox 7 days prior to surgery and this is stopped the day before surgery. following surgery aspirin or coumadin are recommenced 48 hours postop. exclusion criteria: * patients with previous head and neck radiation * pregnant or lactating female patients. * patients with oral cavity squamous cell cancer requiring neck dissection

Keywords: flexible fiber-based co2 laser monopolar cautery oral cavity lesions quality of life assessing pain 11-034
the role of 18f-fdg&68ga-fapi pet/ct in the assessment of conversion therapy efficacy in gastric cancer with peritoneal metastasis.

Conditions: Peritoneal Metastasis; Gastric Cancer

Summary: this study aims to investigate the value of 18f-fdg\&68ga-fapi pet/ct in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.

if the target population of the study agrees to participate in the study, we will number the participants, resume their pathology files, and collect their gender, age, phone number, height and weight information, record the participants\&#39; consultation process and the results of the tests and examinations therein. during the course of the study we will perform 18f-fdg \& 68ga-fapi pet/ct according to the participant\&#39;s stage of disease, specifically: one 18f-fdg pet/ct prior to conversion therapy and one 68ga-fapi pet/ct as a baseline assessment. one 18f-fdg pet/ct and one 68ga-fapi pet/ct were performed before the clinician assessed that the conversion therapy was ready to be completed and the conversion surgery was about to be performed, and if the participant experienced a postoperative recurrence of the disease during the study period, another 18f-fdg pet/ct and a 68ga-fapi pet/ct would be performed, meaning that a total of 4 pet/cts were performed. in other words, a total of 4 pet/ct visualizations were required for all participants; 2 additional pet/ct visualizations, including 18f-fdg pet/ct and 68ga-fapi pet/ct, were performed if the disease recurred after the conversion surgery, and none were required for participants without recurrence.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions 2. peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction 3. patients voluntarily enrolled in this study by signing an informed consent form 4. age ≥ 18 years 5. eastern cooperative oncology group (ecog) score ≤ 2, 6. expected life expectancy ≥ 3 months 7. adequate organ and bone marrow function 8. willingness to adhere to the study protocol and follow-up programme exclusion criteria: 1. signs of distant metastases other than peritoneal metastases at enrolment 2. pregnant or breastfeeding women. 3. patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix 4. severe mental disease, uncontrolled epilepsy, or central nervous system disease

Keywords: 18f-fdg pet/ct 68ga-fapi pet/ct gastric cancer peritoneal metastases conversion therapy
childobesity180 - social marketing campaign to encourage healthful eating in restaurants for children

Conditions: Child Overnutrition

Summary: the purpose of this study is to determine whether a messaging campaign affects the calories ordered for and consumed by children in a quick serve restaurant setting.

childobesity180 seeks to develop and implement a messaging campaign informed by evidence-based behavioral theory as well as perspectives from parents, children, and the restaurant industry. the campaign aims to help parents choose healthful options for their children when dining in the quick-serve restaurant setting. aim 1 is campaign development. aims 2 and 3 are assessment (i.e., randomized controlled trial and revenue analysis). hypotheses are that the messaging campaign will be associated with fewer calories ordered/consumed by children in the quick serve setting; and the campaign will not negatively impact quick serve restaurant revenue.

Eligibility criteria:
inclusion criteria: * parent or legal guardian of a 4 - 12 year old child (who is present) * have not participated in the study before * \ \> live, work, or frequently travel to community exclusion criteria: -
linear ablation versus focal ablation of complex fractionated atrial electrograms in persistent atrial fibrillation

Conditions: Persistent Atrial Fibrillation

Summary: the end point of catheter ablation at complex fractionated atrial electrograms (cfae) was not established yet. furthermore, incomplete cfae ablation may have a potential to develop atrial tachyarrhythmias (at). the investigators hypothesized that linear ablation extending the clusters of cfae would be a better strategy than focal ablation at the individual cfae sites.


Eligibility criteria:
inclusion criteria: * patients age 18 or greater * persistent atrial fibrillation * candidates for af ablation based on af that is symptomatic and refractory to at least one antiarrhythmic medication * at least one episode of af must have been documented by ecg or holter within 12 months of randomization in the trial * continuous anticoagulation with warfarin (inr 2-3) for \>4 weeks prior to the ablation * patients must be able and willing to provide written informed consent to participate in the clinical trial exclusion criteria: * paroxysmal or permanent atrial fibrillation * patients with af felt to be secondary to an obvious reversible cause * inadequate anticoagulation as defined in the inclusion criteria * left atrial thrombus on tee prior to procedure * contraindications to systemic anticoagulation with heparin or coumadin * previously undergone atrial fibrillation ablation * patients who are or may potentially be pregnant
histidine oral supplementation as a therapeutic modality for alzheimer's disease

Conditions: Alzheimer Disease

Summary: oral supplementation of histidine in patients with cognitive dysfunction should increase brain anserine, carnosine and histamine levels which will result in improved cognition via numerous proven in vivo mechanisms including increasing blood flow, neurogenesis, angiogenesis, activation of histaminergic neural pathways and autophagy of beta-amyloid protein, which is pathognomonic for alzheimer's disease. randomized into one of 2 arms to receive histidine or placebo to take for up to 3 months. baseline evaluation and followup evaluation at 3 months postop.

the patients will be offered enrollment by sequential measures with odd numbers placed into the control group and even numbers in the treatment arm. one hundred patients will be enrolled in each arm. study medications will be initiated in the outpatient setting following informed consent, enrollment and baseline lab evaluation. scheduled clinic visits at 3 months and 1 year from date of enrollment will be used to re-assess performance via repeat cognitive testing. lab evaluation of cbc, cmp, histidine and histamine levels will occur at baseline and the 3 month clinic visit for the treatment arm subjects. group i: control arm- no intervention. subjects will receive cognitive and lab testing and continue with current management of their cognitive impairment. group ii: treatment arm- in the outpatient setting, one chewable tablet multivitamin (zn and folic acid containing) plus a titrated dosing of l-histidine powder or capsules starting at 2g consumed before noon escalating every 2 weeks up to 4, 6, then 8 g per day as tolerated.

Eligibility criteria:
inclusion criteria: * \>49 years * live at home currently * clinical dementia score of 3.0 or higher exclusion criteria: * psychiatric
padua prediction score for vte risk in thoracic surgery patients

Conditions: DVT - Deep Vein Thrombosis; VTE (Venous Thromboembolism)

Summary: the goal of this observational study is to assess the predictive accuracy of the padua prediction score (pps) for venous thromboembolism (vte) risk in thoracic surgery patients. the study aims to answer the following question: does the pps provide a more accurate prediction of vte risk? participants will: have their vte risk assessed using the pps during their hospital admission.

venous thromboembolism (vte) is a significant cause of morbidity and mortality, comprising conditions like deep vein thrombosis (dvt) and pulmonary embolism (pe). hospitalized patients are particularly vulnerable to vte due to factors such as prolonged immobility, surgical procedures, and preexisting comorbidities. to address this risk, tools like the padua prediction score (pps) have been developed. pps is a validated scoring system that uses clinical and demographic criteria to categorize patients as high- or low-risk for vte, allowing healthcare providers to tailor prophylactic measures accordingly. although the padua prediction score has been increasingly adopted in various healthcare settings, its applicability in iraq remains understudied. there is limited local data on the prevalence of vte, risk assessment practices and adherence to prophylaxis protocols, leaving a clear gap in the literature. this study aims to explore the utility and predictive accuracy of the padua prediction score in the iraqi healthcare context. by addressing this gap, the findings could help refine vte prevention strategies, improve resource allocation, and ultimately reduce complications associated with this condition.

Eligibility criteria:
inclusion criteria: * patients who have undergone preoperative padua prediction score assessment. * inpatients with a hospital stay over 3 days * written informed consent obtained from patients or their legal guardians. * availability for postoperative follow-up to assess outcomes like levt development or related complications. exclusion criteria: * preexisting levt or pulmonary embolism. * severe coagulopathy: patients with inherited or acquired bleeding disorders (e.g., hemophilia, advanced liver disease). * receiving any anticoagulation therapy for any reason. * patients who did not undergo a postoperative d-dimer test. * incomplete data: missing essential clinical or laboratory data. * pregnancy: pregnant women or those within six weeks postpartum. * noncompliance: patients unwilling or unable to adhere to study follow-up protocols.

Keywords: padua prediction score (pps)
evaluation of fertitonex effects on semen parameters in clinical varicocele patient.

Conditions: Varicocele

Summary: the aim of the study is to evaluate the fertitonex effects on semen parameters in clinical varicocele patients.

infertility is defined as the inability of a couple to conceive after one year of unprotected, frequent and regular sexual intercourse. almost 15% of all couples trying to conceive are affected by infertility, and in almost half of these cases male infertility is the sole or a contributing factor. the most common cause is idiopathic oligoasthenoteratozoospermia (oat) that is defined as follows sperm concentration, the proportion of morphologically normal sperm and the proportion of motile sperm are all lower than the world health organization (who) reference values. despite extensive research, a successful treatment for oat had not yet been developed. small amounts of reactive oxygen species (ros) are produced by spermatozoa in physiological conditions, and various scavengers act to reduce the concentration of these ros in the seminal plasma. ros are needed for capacitation, acrosome reaction and ultimately fertilization. antioxidants might help maintain the balance between ros production and clearance and thus could improve sperm quality additionally, observational studies had found a lower frequency of sperm aneuploidy in men with a higher dietary intake of antioxidants than in those with a lower intake. in semen, antioxidants decrease os, potentially improving sperm motility and reducing dna fragmentation. we aim to evaluate the fertitonex effects on semen parameters in clinical varicocele patients.

Eligibility criteria:
inclusion criteria: * primary infertility. * abnormal semen analysis parameters. * clinically evident varicocele confirmed by scrotal duplex. exclusion criteria: * 2ry infertility. * normal semen analysis parameters. * clinically non-evident varicocele. * past history of varicocelectomy.

Keywords: varicocele fertitonex infertility semen analysis
study to investigate the long-term safety of fab122 in patients with amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: a multicenter, open-label extension study to investigate the long-term safety of fab122 in patients with amyotrophic lateral sclerosis


Eligibility criteria:
inclusion criteria: 1. who completed the full study period in the main adore study (fab122-ct-2001); 2. whom the investigator has no concern and judges tolerable for initiating or continuing treatment with fab122 from a risk and benefit point of view; 3. a female subject should not be able to become pregnant up to 30 days after the last dose of fab122 and needs to meet at least one of the following criteria: * female who is of reproductive potential and has a negative pregnancy test at baseline and is non-lactating. * female subject who is not of reproductive potential is eligible without requiring the use of contraception 4. a male patient must: * agree he will not donate sperm during the period he will be using fab122, and use a condom during sexual intercourse with pregnant or non-pregnant women of childbearing potential exclusion criteria: 1. patient who has a medical condition or personal circumstances which, in the opinion of the investigator, will make initiation or continuation of treatment with fab122 not tolerable for them from a risk and benefit point of view. 2. patient who discontinued study drug prematurely in the double-blind phase of the study (adore study) for safety reasons. 3. patient who has received any other investigational drug within the period between last visit of the main study and first visit of the extension study
phase i/ii study of chemo-immunotherapy combination in melanoma patients

Conditions: Melanoma

Summary: this phase i/ii study is directed at evaluating safety and immunogenicity of a melanoma peptide vaccine in combination or not with dacarbazine administration in melanoma patients

recently, it is becoming increasingly accepted that, in order to induce a clinically effective antitumor response, immunotherapy needs to be combined with chemotherapy. thus, the traditional perception that chemotherapy and immunotherapy act through unrelated mechanisms which may be antagonistic is challenged on the premises that a selected panel of drugs can induce an immunogenic cell death producing specific danger signals. furthermore, chemotherapy combined to immunotherapy may affect antigen cross-presentation, induce a "cytokine storm", reduce the number of regulatory t cells and activate homeostatic lymphoid proliferation. our previous results obtained in a mouse model, demonstrated that drug-induced cytokines can favour antitumor immunity. based on this observation, we explored whether the administration of dacarbazine (dtic) in disease-free melanoma patients in combination with peptide vaccination could result into an improved anti tumor immune response. patients included in the study were assigned to two treatment arms either receiving anti-tumor vaccination with melan-a and gp100 analog peptides alone (arm 1) or in combination with dtic pre-treatment (arm 2). arm 1, vaccine alone: patients received i.d. injections of melan-a: 26-35 (a27l) and gp100: 209-217 (210m) peptides (250 µg each) formulated in montanide isa-51 plus s.c. injection of 3mu ifn-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses (10 vaccinations). both peptides and ifn-α were injected in close but separate sites next to local lymph nodes. arm 2, dtic plus vaccine: the same vaccination schedule was combined with dtic (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.

Eligibility criteria:
inclusion criteria: * histologically proven diagnosis of melanoma stage ii, iii, and iv without clinical/radiological evidence of disease * age \>18 years * life expectancy of more than 6 months * ecog performance status of 0-2 * adequate blood cell counts and kidney-liver function * use of adequate contraceptive methods * signed informed consent exclusion criteria: * concomitant or previous history of malignant disease, except for in situ cervical carcinoma or non melanomatous skin cancer * severe cardiovascular disease * clinically active infections and/or significant autoimmune diseases * concomitant or previous (within 6 weeks) treatment with immunosuppressive drugs * previous treatments with chemotherapy and/or interferon alpha or beta within 4 weeks and/or radiotherapy within 6 weeks an/or biological therapy within 8 weeks before starting vaccination * psychiatric illness interfering with patient compliance, pregnancy or lactation
understanding ayurveda disease conditions and treatment responses

Conditions: Type2diabetes; Rheumatoid Arthritis; Osteo Arthritis Knee; Skin Diseases; Gastric Ulcer; Neurodegenerative Diseases

Summary: the goal of this observational study is to assess prakriti \& vikriti in patients visiting opd of iiism department, srm hospital. the main question\[s\] it aims to answer are: * to evaluate prakriti \& vikriti of patients using prakriti \& vikriti questionnaire and with digital devices * to correlate the determined prakriti and vikriti with the doctor's assessment along with clinical and biochemical parameters participants will be advised to follow the treating physician's advice on medicines

the ayurveda is an ancient documented medical system originated in india. the ayurveda stratified humans into 7 broad categories based on the phenotype features viz. vata, pitta, kapha, vatapitta, vatakapha, kaphapitta and vatapittakapha prakriti types. also, the features of the disease conditions are clearly described based on the predominance of vata, pitta and kapha or its combinations. presently, the identification of prakriti type and vikriti status are basically subjective assessment. this study proposes to integrate the subjective assessment with objective digital signal parameters. this digital signatures would be useful in ml / ai based assessment and prediction of prakriti type and vikriti status of the patients.

Eligibility criteria:
inclusion criteria: * patients of various diseases visiting the opd exclusion criteria: * pregnancy and lactating females